Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.05.10 | Developmental and paediatric endocrinology | ECE2015

Ghrelin and GHSR1 receptor in placentas of SGA, LGA, and AGA newborns

Gonzalez Dominguez Martha I , de la Vega Monrroy Maria Luisa Lazo , Zaina Silvio , Sabanero Myrna , Daza-Benitez Leonel , Malacara Juan Manuel , Barbosa-Sabanero Gloria

Introduction: Intrauterine growth is a biological process regulated by maternal, placental, and foetal endocrine signals. Birth weight is an indicator of the health of the newborn. Alterations in foetal growth lead to perinatal health risks and favour metabolic diseases during adult life. Therefore, the study of endocrine factors determining birth weight, such as ghrelin is an important issue. Ghrelin may exist as two molecular forms, desacyl ghrelin (DAG) and acyl ghrelin (AG...

ea0090ep8 | Adrenal and Cardiovascular Endocrinology | ECE2023

Metabolic changes in transgender people after gender-affirming hormone therapy

Toscano Esteban Sanchez , Gavira Isabel Mateo , Riscart Jesus Dominguez

Introduction: Demand for health care for transsexual people has increased exponentially in last years, especially among adolescents and young adults. Gender-affirming hormones (GAHs) are initiated to accommodate secondary sexual characteristics to the desired sex. Published studies about metabolic repercussion of GAHs are heterogeneous and report diverse results. Our objective is to evaluate the effect of GAHs on cardiovascular risk factors in transsexual population treated in...

ea0063p766 | Thyroid 2 | ECE2019

Is the determination of rTSH estimulated thyroglobulin necessary for long term management in patients with differentiated thyroid carcinoma?

Cozar Miriam , Romero Ana , Duenas Suset , Dominguez Inmaculada , Navarro Elena

Introduction: In clinical practice guidelines for differentiated thyroid cancer (DTC) it has been proposed to perform thyroglobulin (Tg) stimulated by rTSH determination 6–12 months after initial therapy in patients with low or intermediate risk, in order to establish the absence of disease. The use of ultrasensitive Tg assays could avoid the need of stimulation to establish the absence of disease.Objectives: To evaluate the usefulness of the determ...

ea0032p275 | Clinical case reports - Thyroid / Others | ECE2013

Submandibular ectopic thyroid gland

Dominguez-Lopez Marta , Gonzalez-Molero Inmaculada , Ruiz MSol , Soriguer Federico

Introduction: Ectopic thyroid glands are generally a rare entity appearing mostly in the cervical midline (90% of the cases) and even more rarely in other anatomical sites (10%).Clinical report: We present the case of an ectopic submandibular thyroid gland. A 31-year-old woman was referred to our department with a history of left submandibular swelling.A scintigraphy was performed, which showed an accumulation of activity in the ri...

ea0032p343 | Developmental Endocrinology | ECE2013

Evaluation of adults with phenyketonuria from pediatric to adult care

Gonzalo Montserrat , Omiste Antonio , Gonzalez Inmaculada , Dominguez Marta

Objective: Transition from pediatric to adult health care is a particularly vulnerable period for patients with inborn metabolic diseases.Our objective in this study was to evaluate the current transition of patients with phenylketonuria (PKU) in Malaga, Spain, by analysis of the metabolic control, medical care, patients satisfaction and phychosocial status.Material and methods: We evaluate all the patients transferred to our adult...

ea0032p485 | Diabetes | ECE2013

Efficacy and safety of liraglutide in morbid obese patients in first year of commercialization in Spain

Molero Inmaculada Gonzalez- , Vallejo Rosario , Dominguez Marta , Garcia-Arnes Juan

Aim: To evaluate the efficacy and safety for first patients treated in our clinic with liraglutide.Methods: Retrospective study of patients who started treatment with liraglutide in the last year in our department. We collected data on age, years of evolution, chronic complications, previous treatment, physical examination, analytical parameters and side effects.Results: Fifty-four patients. Follow-up: 4–12 months. Mean age: 5...

ea0029p1084 | Neuroendocrinology | ICEECE2012

Long term evolution of patients with transsphenoidal surgery due to pituitary adenomas

Arnes J Garcia . , Gonzalez-Molero I. , Dominguez-Lopez M.

Aim: To study the results of transsphenoidal surgery in our Neuroendocrinology Unit in last 10 years.Methods: We reviewed all patients operated in our hospital and followed in our Neuroendocrinology Unit in the last 10 years. We excluded patients with previous surgery or irradiation on this area. We obtained data about type and size of tumor, previous hormonal deficit, local symptoms,complications of surgery and the status after this (remission, persiste...

ea0029p1088 | Neuroendocrinology | ICEECE2012

Long term evolution of patients with prolactinoma in a neuroendocrinology unit

Arnes JGarcia , Gonzalez-Molero I , Dominguez-Lopez M

Aims: To know characteristics and long term evolution of patients with prolactinoma in our Neuroendocrinology Unit.Material and methods: We studied retrospectively all patients with diagnosis of prolactinoma in our Neuroendocrinology Unit in last 12 years.Results: We studied 126 patients. Predominant sex was female (69.07%), 56.7% were macroadenomas. The time from the onset of symptoms until they are seen by the specialist ranges 1...

ea0026p212 | Pituitary | ECE2011

Efficacy and safety of the use of the recombinant GH receptor antagonist pegvisomant (PGV) in acromegaly. Evaluation of its use in 13 patients treated in a pituitary disorders unit

Dominguez-Lopez M , Gonzalez-Molero I , Garcia-Arnes J

Introduction: The recombinant GH receptor antagonist pegvisomant (PGV) is actually used for the treatment of acromegaly when surgery and medical therapy with somatostatin analogues (SSA) have failed. Long term safety and effectiveness need to be evaluated.Material and methods: Retrospective analysis of clinical data from all patients treated with pegvisomant in a pituitary disorders unit.Results: Thirteen patients are being treated...

ea0020p684 | Signal Transduction | ECE2009

Nuclear orphan receptor Nur77 is a mediator of p53-dependent apoptotic response

Sanguinetti Dolores , Carneiro Carmen , Martinez Gloria , Dominguez Fernando , Vidal Anxo

Nur77 is a nuclear orphan receptor belonging to the steroid receptor superfamily. A role for Nur77 has been described in proliferation, differentiation and apoptosis, as a result of its induction in response to multiple signal transduction pathways. Previous studies have suggested that physical interaction between Nur77 and the tumor suppressor p53 can prevent p53 ubiquination and subsequent degradation by hMdm2. This suggests a possible role for Nur77 as a regulator of p53-de...